Art. -Nr.: HY-12702

10058-F4

56 Cited Publications

Kundenbewertung

Based on 56 publication(s) in Google Scholar

10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.90%
CAS. Nr.: 403811-55-2
Formel: C₁₂H₁₁NOS₂
Molecular Weight:249.35

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

10058-F4 Chemical Structure

CAS. Nr.: 403811-55-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (56)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.

In Vitro

10058-F4 inhibits growth of leukemic cells and dimerization of Myc and Max. 10058-F4 induces cell-cycle arrest and apoptosis of AML cells. 10058-F4 arrests AML cells at G0/G1 phase, downregulates c-Myc expression and upregulated CDK inhibitors, p21 and p27. Meanwhile, 10058-F4 induces apoptosis through activation of mitochondrial pathway shown by downregulation of Bcl-2, upregulation of Bax, release of cytoplasmic cytochrome C, and cleavage of caspase 3, 7, and 9. Furthermore, 10058-F4 also induces myeloid differentiation, possibly through activation of multiple transcription factors. Similarly, 10058-F4-induced apoptosis and differentiation could also be observed in primary AML cells^[1].
10058-F4 decreases c-Myc protein levels, inhibites proliferation of HepG2 cells likely through upregulation of cyclin-dependent kinase (cdk) inhibitor, p21WAF1 and lowers intracellular levels of [alpha]-fetoprotein (AFP). Treatment with 10058-F4 also downregulates human telomerase reverse transcriptase (hTERT) at the transcriptional level. In addition to inhibiting the proliferation of HepG2 cells, 10058-F4 enhances sensitivity to conventional chemotherapeutic agents, doxorubicin, 5-fluorouracil (5-FU) and cisplatin^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Peak plasma 10058-F4 concentrations of approximately 300 μM are seen at 5 min and declined to below the detection limit at 360 min following a single iv dose. Plasma concentration versus time data are best approximated by a two-compartment, open, linear model. The highest tissue concentrations of 10058-F4 are found in fat, lung, liver, and kidney. Peak tumor concentrations of 10058-F4 are at least tenfold lower than peak plasma concentrations. Eight metabolites of 10058-F4 are identified in plasma, liver, and kidney. The terminal half-life of 10058-F4 is approximately 1 h, and the volume of distribution is > 200 mL/kg. No significant inhibition of tumor growth is seen after i.v. treatment of mice with either 20 or 30 mg/kg 10058-F4^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 403811-55-2
Appearance Solid
Molecular Weight 249.35
Formel C₁₂H₁₁NOS₂
Color Light yellow to yellow
SMILES

O=C1NC(S/C1=C/C2=CC=C(CC)C=C2)=S
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (56)

All Cell Proliferation/Viability AssayWBIn Vivo Efficacy StudyRT-PCR

Sort by:

Journal Impact Factor

Nature

Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. [Abstract]

2024 Jun;630(8018):968-975. PMID: 38867043

10058-F4 purchased from MedChemExpress. Usage Cited in: Nature. 2024 Jun;630(8018):968-975. [Abstract]

Percent viability BMDMs stimulated with LPS (1ug/mL) and treated with c-Myc inhibitors (KJ Pyr 9 10ug/mL and 10058-F4 10ug/mL), mTOR inhibitor (Rapamycin 250 ng/mL), AMPK agonist (AICAR 2ug/mL) and NF-κB inhibitor (BMS-345541 1.2ug/mL) for 24 h.
J Hematol Oncol

CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. [Abstract]

2020 Feb 5;13(1):11. PMID: 32024555

10058-F4 purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2020 Feb 5;13(1):11. [Abstract]

Effects of c-Myc antagonist 10058-F4 (5 μM) treatment on SOX9 mRNA and protein expression levels in CD73-overexpressing hepatocellular carcinoma cells.
Mol Cancer

A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression. [Abstract]

2024 Jul 9;23(1):141. PMID: 38982480
Cell Metab

Lactate controls cancer stemness and plasticity through epigenetic regulation. [Abstract]

2025 Apr 1;37(4):903-919.e10. PMID: 39933514
Mil Med Res

Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability. [Abstract]

2022 Sep 27;9(1):54. PMID: 36163081

10058-F4 purchased from MedChemExpress. Usage Cited in: Mil Med Res. 2022 Sep 27;9(1):54. [Abstract]

Representative Western blotting results of c-Myc, HDAC7, p21, p27 and Cyclin D1 in the EC109 and EC9706 cells with 10058-F4 (0-0.3 mM; 48 h) treatment.
Nat Metab

Intestinal MYC modulates obesity-related metabolic dysfunction. [Abstract]

2021 Jul;3(7):923-939. PMID: 34211180

10058-F4 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Jul;3(7):923-939. [Abstract]

The levels of total GLP-1 and active GLP-1 in the culture medium of intestinal organoids isolated from Mycfl/+ mice fed a HFD for 2 weeks and treated with vehicle or 10058-F4 (40 μM; 24 h).

10058-F4 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2021 Jul;3(7):923-939. [Abstract]

mRNA levels of indicated genes in the intestinal organoids isolated from Mycfl/+ mice fed a HFD for 2 weeks and treated with vehicle or 10058-F4(20 μM or 40 μM; 24 h).
Nat Commun

8q24 derived ZNF252P promotes tumorigenesis by driving phase separation to activate c-Myc mediated feedback loop. [Abstract]

2025 Feb 26;16(1):1986. PMID: 40011431
Adv Sci (Weinh)

TRIM47 Regulates Energy Metabolism via Glycolytic Reprogramming to Drive Hepatocellular Carcinoma Progression and Represents an Efficient Therapeutic Target. [Abstract]

2026 Mar;13(17):e16996. PMID: 41632101
Adv Sci (Weinh)

Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer. [Abstract]

2025 Jan 30:e2413445. PMID: 39887933
Adv Sci (Weinh)

Glutamine Metabolism Underlies the Functional Similarity of T Cells between Nile Tilapia and Tetrapod. [Abstract]

2023 Apr;10(12):e2201164. PMID: 36890649
J Adv Res

c-Myc-PANK3-EMT axis regulates the structure and function of intestinal barrier in ulcerative colitis. [Abstract]

2025 Dec 8:S2090-1232(25)00996-8. PMID: 41371401
J Exp Clin Cancer Res

TRAF2 promotes M2-polarized tumor-associated macrophage infiltration, angiogenesis and cancer progression by inhibiting autophagy in clear cell renal cell carcinoma. [Abstract]

2023 Jul 6;42(1):159. PMID: 37415241
Sci Adv

Role of CEBPa in trophectoderm competence installment. [Abstract]

2025 Nov 28;11(48):eady1693. PMID: 41313781
Redox Biol

MIOX inhibits autophagy to regulate the ROS -driven inhibition of STAT3/c-Myc-mediated epithelial-mesenchymal transition in clear cell renal cell carcinoma. [Abstract]

2023 Dec:68:102956. PMID: 37977044
Mol Biomed

GEF-independent Ran activation shifts a fraction of the protein to the cytoplasm and promotes cell proliferation. [Abstract]

2020 Dec 30;1(1):18. PMID: 35006421
Cell Death Dis

TGF-β1 facilitates gallbladder carcinoma metastasis by regulating FOXA1 translation efficiency through m6A modification. [Abstract]

2024 Jun 17;15(6):422. PMID: 38886389
Cell Death Dis

HDAC7/c-Myc signaling pathway promotes the proliferation and metastasis of choroidal melanoma cells. [Abstract]

2023 Jan 18;14(1):38. PMID: 36653340
Cell Death Dis

Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage. [Abstract]

2022 Apr 12;13(4):338. PMID: 35414060
Cell Death Dis

Overexpression of Annexin A2 promotes proliferation by forming a Glypican 1/c-Myc positive feedback loop: prognostic significance in human glioma. [Abstract]

2021 Mar 12;12(3):261. PMID: 33712571
Cell Death Dis

A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors. [Abstract]

2020 Nov 15;11(11):982. PMID: 33191401
Cell Death Dis

PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis. [Abstract]

2018 Feb 22;9(3):307. PMID: 29472550

10058-F4 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 22;9(3):307. [Abstract]

ACHN cells are treated with or without 10058-F4 for 24 h. After the 24-h treatment, proteins are extracted. Immunoblotting assays are performed to analyse E-cadherin, N-cadherin, Vimentin, ZEB1, ZEB2, Snail1, Snail2, Twist, Smad2, Smad3, p-Smad2 and p-Smad3 protein levels. GAPDH is used as the loading control.

10058-F4 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 22;9(3):307. [Abstract]

786-O cells are treated with or without 10058-F4 for 24 h. After the 24-h treatment, proteins are extracted. Immunoblotting assays are performed to analyse E-cadherin, N-cadherin, Vimentin, ZEB1, ZEB2, Snail1, Snail2 , Twist, Smad2, Smad3, p-Smad2 and p-Smad3 protein levels. GAPDH is used as the loading control.
Genes Dis

2026 Feb 14.
Proc Natl Acad Sci U S A

Local translation in nuclear condensate amyloid bodies. [Abstract]

2021 Feb 16;118(7):e2014457118. PMID: 33568529
Phytomedicine

Flemiphilippinin A induces paraptosis in lung cancer cells via c-Myc-driven endoplasmic reticulum stress and CHOP-mediated mitochondrial dysfunction. [Abstract]

2025 Oct:146:157098. PMID: 40716126
Phytomedicine

Antileukemic effect of caffeic acid 3,4-dihydroxyphenetyl ester. Evidences for its mechanisms of action. [Abstract]

2021 Jan;80:153383. PMID: 33091855
Biomed Pharmacother

c-Myc-XRCC2-FOS axis promotes the proliferation and the resistance to Doxorubicin of NSCLC. [Abstract]

2024 Aug 16:179:117315. PMID: 39153434
Oncogene

LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation. [Abstract]

2021 Apr;40(14):2581-2595. PMID: 33686242
Oncogene

C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma. [Abstract]

2020 Apr;39(16):3354-3366. PMID: 32103167
Cell Rep

SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer. [Abstract]

2023 Nov 18;42(12):113434. PMID: 37980563
Cell Rep

CD226 maintains regulatory T cell phenotype stability and metabolism by the mTOR/Myc pathway under inflammatory conditions. [Abstract]

2023 Oct 20;42(10):113306. PMID: 37864795
Antioxidants (Basel)

Alpha-Lipoic Acid Inhibits IFN-γ-Induced PD-L1 Expression in Prostate Cancer Cells and Enhances T-Cell-Mediated Anti-Tumor Cytotoxicity. [Abstract]

2026 Mar 25;15(4):413. PMID: 42072056
Oncogenesis

ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis. [Abstract]

2020 Apr 29;9(4):42. PMID: 32350243
Mol Ther Nucleic Acids

2025 Dec 15.
Front Immunol

EST12 regulates Myc expression and enhances anti-mycobacterial inflammatory response via RACK1-JNK-AP1-Myc immune pathway. [Abstract]

2022 Aug 8;13:943174. PMID: 36003390
J Invest Dermatol

CXCL12/CXCR4 Axis Drives the Chemotaxis and Differentiation of B Cells in Bullous Pemphigoid. [Abstract]

2023 Feb;143(2):197-208.e6. PMID: 36075452
Biochem Pharmacol

Hydroquinone-selected chronic myelogenous leukemia cells are sensitive to chloroquine-induced cytotoxicity via MCL1 suppression and glycolysis inhibition. [Abstract]

2023 Dec:218:115934. PMID: 37989415
Chem Biol Interact

Interfering TRIB3 protects the blood brain barrier through PI3K/Akt pathway to alleviate cerebral ischemia-reperfusion injury in diabetes mellitus mice. [Abstract]

2024 Jan 5:387:110807. PMID: 37980971
Mol Ther Oncolytics

Insulin and Metformin Control Cell Proliferation by Regulating TDG-Mediated DNA Demethylation in Liver and Breast Cancer Cells. [Abstract]

2020 Jun 24;18:282-294. PMID: 32728616
Commun Biol

The role of IGF2BP3/SPOP/c-Myc loop in paclitaxel resistance of endometrial cancer. [Abstract]

2025 Apr 17;8(1):624. PMID: 40247055
Int J Oncol

Anti‑silencing function 1B promotes the progression of pancreatic cancer by activating c‑Myc. [Abstract]

2023 Jan;62(1):8. PMID: 36416310
Mol Oncol

Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. [Abstract]

2018 Dec;12(12):2191-2208 PMID: 30353671
Cancers (Basel)

A Combinatorial Regulatory Platform Determines Expression of RNA Polymerase III Subunit RPC7α (POLR3G) in Cancer. [Abstract]

2023 Oct 15;15(20):4995. PMID: 37894362
iScience

TFAP2A enhances tumor stemness and promotes metastasis in pancreatic ductal adenocarcinoma. [Abstract]

2025 Jul 5;28(8):113060. PMID: 40727938
Neurochem Int

IFN-γ regulates the transformation of microglia into dendritic-like cells via the ERK/c-myc signaling pathway during cerebral ischemia/reperfusion in mice. [Abstract]

2020 Dec;141:104860. PMID: 33022312
Cell Signal

LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway. [Abstract]

2024 Mar:115:111039. PMID: 38199599
Bone

HIF-1α mediates osteoclast-induced disuse osteoporosis via cytoophidia in the femur of mice. [Abstract]

2023 Mar:168:116648. PMID: 36563716
J Immunol

Fish requires FasL to facilitate CD8+ T-cell function and antimicrobial immunity. [Abstract]

2025 Jun 1;214(6):1219-1235. PMID: 40073091
Dev Comp Immunol

Molecular cloning and functional characterization of MYC transcription factor in pathogen-challenged Apostichopus japonicus. [Abstract]

2020 Jan;102:103487. PMID: 31472172
Comp Biochem Physiol A Mol Integr Physiol

Osmoregulation by the myo-inositol biosynthesis pathway in turbot Scophthalmus maximus and its regulation by anabolite and c-Myc. [Abstract]

2020 Apr;242:110636. PMID: 31846703
Eur J Integr Med

2025 Aug 28;78:102545.
bioRxiv

Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells. [Abstract]

2026 May 22:2026.05.20.726663. PMID: 42239313
bioRxiv

2026 Feb 2.
Res Sq

2026 Feb 23.
ASPET Discov

2025 Sep 2.
bioRxiv

ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. [Abstract]

2024 Mar 13:2024.03.12.584316. PMID: 38903083
Research Square Preprint

2020 Aug.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (200.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0104 mL

20.0521 mL

40.1043 mL

5 mM

0.8021 mL

4.0104 mL

8.0209 mL

10 mM

0.4010 mL

2.0052 mL

4.0104 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.83 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.83 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.83 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

Cells, plated in 96-well plates (10⁵/mL for cell lines and 5×10⁵/mL for primary leukemic cells), are treated in triplicate with indicated concentrations of 10058-F4. At various time points, 20 μL 5 mg/mL MTT is added to each well. After incubation at 37°C for 3 hours, the MTT medium is removed and 100 μL DMSO lysis buffer is added. The number of viable cells is assessed by the percentage of absorbance of treated cells relative to that of solvent controls, using 570-nm wavelength on a spectrophotometer.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

C B-17 SCID mice bearing PC-3 human prostate tumor xenografts are stratified into the following groups: Control, vehicle control, positive control (docetaxel, 10 mg/kg), and 10058-F4 treatment (20 or 30 mg/kg/dose). Previous studies by us indicates that 30 mg/kg is the maximally tolerated dose of 10058-F4 on this schedule. Mice are treated i.v. daily for 5 days for 2 weeks, and body weights and tumor volumes are recorded twice weekly. In the second study, C B-17 SCID mice bearing DU145 human androgen-independent prostate cancer xenografts are stratified to similar treatment groups. Docetaxel serves as the positive control for both efficacy studies and is administered i.v. every 7 days for two doses of 10 mg/kg. Tumors are measured with calipers, and tumor volumes are calculated using the formula: TV= L×W²/2 where L is the largest diameter of the tumor and W is the smallest diameter perpendicular to L. Mice are followed for at least 1 week following the completion of the dosing so that tumor regrowth could be monitored.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Huang MJ, et al. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol. 2006 Nov;34(11):1480-9. [Content Brief]

[2]. Lin CP, et al. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs. 2007 Feb;18(2):161-70. [Content Brief]

[3]. Guo J, et al. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.0104 mL	20.0521 mL	40.1043 mL	100.2607 mL
	5 mM	0.8021 mL	4.0104 mL	8.0209 mL	20.0521 mL
	10 mM	0.4010 mL	2.0052 mL	4.0104 mL	10.0261 mL
	15 mM	0.2674 mL	1.3368 mL	2.6736 mL	6.6840 mL
	20 mM	0.2005 mL	1.0026 mL	2.0052 mL	5.0130 mL
	25 mM	0.1604 mL	0.8021 mL	1.6042 mL	4.0104 mL
	30 mM	0.1337 mL	0.6684 mL	1.3368 mL	3.3420 mL
	40 mM	0.1003 mL	0.5013 mL	1.0026 mL	2.5065 mL
	50 mM	0.0802 mL	0.4010 mL	0.8021 mL	2.0052 mL
	60 mM	0.0668 mL	0.3342 mL	0.6684 mL	1.6710 mL
	80 mM	0.0501 mL	0.2507 mL	0.5013 mL	1.2533 mL
	100 mM	0.0401 mL	0.2005 mL	0.4010 mL	1.0026 mL

Keywords

10058-F4

56 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

10058-F4

Publications Citing Use of MedChemExpress (MCE) 10058-F4

Biologische Aktivität

Chemical Information

Publications (56)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

10058-F4 Related Classifications

Art. -Nr.: HY-12702